Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of sifalimumab in adults with systemic lupus erythematosus
NL-OMON35833Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sifalimumab in systemic lupus erythematosus (SLE) (4 arms), sponsored by AstraZeneca. Primary endpoint: Efficacy at Day 365. Started Jan 2012; status: active, not recruiting.
02
Drugs
sifalimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON35833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35833.